| アブストラクト | OBJECTIVES: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England. METHODS: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode Statistics. Patients diagnosed with CDI in hospital and community settings during 2015-2018 were included and followed for >/=1 year. All-cause mortality was described at 6, 12, and 24 months. Healthcare resource usage (HCRU) and associated costs were assessed at 12 months of follow-up. A cohort of non-CDI patients, matched by demographic and clinical characteristics including Charlson Comorbidity Index score, was used to assess excess mortality and incremental costs of HCRU. RESULTS: All-cause mortality among CDI patients at 6, 12, and 24 months was 15.87%, 20.37%, and 27.03%, respectively. A higher proportion of rCDI patients died at any point during follow-up. Compared with matched non-CDI patients, excess mortality was highest at 6 months with 1.81 and 2.53 deaths per 100 patient-months among CDI and >/=1 rCDI patients. Hospitalizations were the main drivers of costs, with an incremental cost of pound1209.21 per CDI patient. HCRU and costs increased with rCDIs. CONCLUSION: CDI poses a substantial mortality and economic burden, further amplified by rCDIs. |
|---|
| ジャーナル名 | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |
|---|
| Pubmed追加日 | 2024/2/19 |
|---|
| 投稿者 | Ghosh, Subrata; Antunes, Ana; Rinta-Kokko, Hanna; Chaparova, Elena; Lay-Flurrie, Sarah; Tricotel, Aurore; Andersson, Fredrik L |
|---|
| 組織名 | College of Medicine and Health, University College Cork, Cork, Ireland;;University of Birmingham, Birmingham, United Kingdom.;IQVIA, Global Database Studies, Real World Solutions, Lisbon, Portugal.;Electronic address: ana.antunes@iqvia.com.;IQVIA, Global Database Studies, Real World Solutions, Espoo, Finland.;IQVIA, Real World Solutions, Sofia, Bulgaria.;IQVIA, Real World Solutions, London, United Kingdom.;IQVIA, Real World Solutions, Paris, France.;Ferring Pharmaceuticals, Copenhagen, Denmark. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38368927/ |
|---|
